Shandong Polymer Biochemicals Co Ltd (002476) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Shandong Polymer Biochemicals Co Ltd ¥0.95, price ¥4.98, upside -80.9%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shandong Polymer Biochemicals Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥3.38 – ¥7.88 · fair‑value band ¥0.8500 – ¥1.09 · the ¥4.98 price screens above the ¥0.9500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Shandong Polymer Biochemicals Co in your weekly email
Every Wednesday you see whether Shandong Polymer Biochemicals Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shandong Polymer Biochemicals Co., Ltd., together with its subsidiaries, produces and sells chemicals for oil and gas exploitation in China and internationally. The company offers monomers, surface active agent, and polymers.
Show more
Shandong Polymer Biochemicals Co., Ltd., together with its subsidiaries, produces and sells chemicals for oil and gas exploitation in China and internationally. The company offers monomers, surface active agent, and polymers. It also provides oil field stimulation and oil recovery technical services; and environmental protection water treatment products and technical services. The company was founded in 1996 and is headquartered in Dongying, China.
Stock analysis
Shandong Polymer Biochemicals Co Ltd (002476) currently trades at ¥4.98, while our model-based Fair Value estimate is ¥0.9500, implying the stock looks roughly 424.1% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥1.27 per share, and 0 of the 25 models we run sit above the ¥4.98 price.
Bear case: the Dividend Discount group reads lowest at ¥0.1700, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.8500 (bear) to ¥1.09 (bull), the price of ¥4.98 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shandong Polymer Biochemicals Co Ltd reported revenue of 603M CNY in FY2025 versus 657M CNY in FY2021, a compound −2.1%/yr. Reported net income was 31.3M CNY in FY2025, compounding +14.9%/yr from FY2021.
Key figures
Market cap 3.3B CNY (≈ $496M) · P/E ratio 99.6 · P/S ratio 5.17 · EPS (TTM) ¥0.0500 · Dividend yield 0.2% · Net margin 5.2% · Return on equity 3.2% · Return on assets (EBIT) 2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 2% fair-value upside, at −81%, 002476 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.1700 to ¥1.54). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥0.8500Fair Value ¥0.9500Bull ¥1.09
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0366 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic). Over 10 years: −2.0% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+12.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.8%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12% vs 3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 4%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 2.4%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+77.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +74.9% a year for the price.
Compare Shandong Polymer Biochemicals Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 355 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−81% · Bottom 25%
Profitability
Return on equity (TTM)3% · Below median
Return on assets2% · Below median
Net margin (TTM)4% · Above median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth78% · Top 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Chemicals median · lower = cheaper
P/E (TTM)99.6× · Priciest 25%
P/B3.50× · Priciest 25%
P/S (TTM)4.73× · Priciest 25%
P/FCF105.4× · Priciest 25%
EV/EBITDA61.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 24
PAST (return on equity)13· sector 19
HEALTH (low debt)100· sector 94
DIVIDEND (yield)5· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shandong Polymer Biochemicals Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002476
Frequently asked questions
Is Shandong Polymer Biochemicals Co Ltd (002476) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥0.9500 versus a price of ¥4.98, about −81% upside (overvalued).
What is the fair value of 002476?
Our model-based fair value for Shandong Polymer Biochemicals Co Ltd is ¥0.9500 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥4.98.
What is the quality score of 002476?
Shandong Polymer Biochemicals Co Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Polymer Biochemicals Co Ltd (002476)?
Our model-based price target is the fair value of ¥0.9500 (as of Sep 23, 2026) from 25 valuation models. Cautious scenario ¥0.8500, optimistic scenario ¥1.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Polymer Biochemicals Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.9500, about −81% upside versus a price of ¥4.98 (overvalued). Cautious scenario ¥0.8500, optimistic scenario ¥1.09. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Polymer Biochemicals Co Ltd (002476)?
Shandong Polymer Biochemicals Co Ltd reported trailing-twelve-month revenue of about 703M CNY (latest available figure, as of Sep 23, 2026).
Does Shandong Polymer Biochemicals Co Ltd pay a dividend?
Shandong Polymer Biochemicals Co Ltd currently shows a dividend yield of about 0.23% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Shandong Polymer Biochemicals Co Ltd (002476)?
For today's price to be fair in a discounted-cash-flow model, Shandong Polymer Biochemicals Co Ltd would have to grow free cash flow by +77.9 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 002476 use?
Our models discount Shandong Polymer Biochemicals Co Ltd at 9.1 %: a base by market capitalisation (mid), damped by beta 0.46, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shandong Polymer Biochemicals Co Ltd that is +77.9 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Shandong Polymer Biochemicals Co Ltd (002476) delivered so far?
Over the past 5 years revenue at Shandong Polymer Biochemicals Co Ltd grew +6.2 % a year. The price currently implies +77.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shandong Polymer Biochemicals Co Ltd (002476) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Shandong Polymer Biochemicals Co Ltd (+77.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shandong Polymer Biochemicals Co Ltd (002476)?
The free-cash-flow yield on the price is 0.15 %: that much free cash flow Shandong Polymer Biochemicals Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shandong Polymer Biochemicals Co Ltd (002476)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Polymer Biochemicals Co Ltd it is ¥0.9500 per share (as of Sep 23, 2026), against a price of ¥4.98. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Shandong Polymer Biochemicals Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 002476 trades above its calculated fair value: price ¥4.98, fair value ¥0.9500, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002476?
No. The price is what the market pays today (¥4.98); the fair value is what the company's own numbers justify (¥0.9500). For Shandong Polymer Biochemicals Co Ltd the two are ¥4.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Polymer Biochemicals Co Ltd worth?
The market values Shandong Polymer Biochemicals Co Ltd at about 3.3B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥4.98; our models calculate a fair value of ¥0.9500 per share.
What do the bullish and bearish scenarios say about 002476?
Our models span a range for Shandong Polymer Biochemicals Co Ltd: cautious scenario ¥0.8500, base ¥0.9500, optimistic ¥1.09 per share (as of Sep 23, 2026, price ¥4.98). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002476?
Shandong Polymer Biochemicals Co Ltd trades at a price-to-earnings ratio of 99.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥0.9500 is built from several models across several years. Other multiples: P/B 3.5, P/S 4.7, EV/EBITDA 61.1.
How solid is the balance sheet of Shandong Polymer Biochemicals Co Ltd (002476)?
Balance-sheet figures for Shandong Polymer Biochemicals Co Ltd (as of Sep 23, 2026): return on equity 3.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 002476 from its 52-week high?
Shandong Polymer Biochemicals Co Ltd trades at ¥4.98, about 37% below its 52-week high of ¥7.88 and 21% above the low of ¥4.13 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.9500 is for.
Which stocks are comparable to Shandong Polymer Biochemicals Co Ltd?
From the same area (Basic Materials) we also value BASF SE, Ningxia Baofeng Energy Group, Dow Inc, Zhejiang Juhua Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Polymer Biochemicals Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price ¥4.98, calculated fair value ¥0.9500 (−81%), Quality Score 60/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002476 calculated?
We run Shandong Polymer Biochemicals Co Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.9500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Shandong Polymer Biochemicals Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Polymer Biochemicals Co Ltd (002476)?
The closing price on Sep 22, 2026 was ¥4.98. Our model-based fair value is ¥0.9500, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Polymer Biochemicals Co Ltd right now?
The price sits above even our optimistic bull case (¥1.09). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Shandong Polymer Biochemicals Co Ltd (002476) come from?
Earnings per share at Shandong Polymer Biochemicals Co Ltd grew −4.5 % a year from 2013 to 2024. Broken into its drivers: revenue per share −3.0 %, EBIT margin −2.9 %, tax rate +0.8 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shandong Polymer Biochemicals Co Ltd
How large is the market capitalisation of Shandong Polymer Biochemicals Co Ltd (002476)?
The market capitalisation of Shandong Polymer Biochemicals Co Ltd is 3.3B CNY (≈ $496M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Polymer Biochemicals Co Ltd (002476)?
The price-to-sales ratio of Shandong Polymer Biochemicals Co Ltd is 5.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Polymer Biochemicals Co Ltd (002476)?
Earnings per share at Shandong Polymer Biochemicals Co Ltd are ¥0.0500 (price ÷ EPS = P/E 99.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shandong Polymer Biochemicals Co Ltd (002476)?
The dividend yield of Shandong Polymer Biochemicals Co Ltd is 0.2% (payout 22.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shandong Polymer Biochemicals Co Ltd (002476)?
The net margin of Shandong Polymer Biochemicals Co Ltd is 5.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Polymer Biochemicals Co Ltd (002476)?
The return on equity (ROE) of Shandong Polymer Biochemicals Co Ltd is 3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Polymer Biochemicals Co Ltd (002476)?
On an EBIT basis the return on assets of Shandong Polymer Biochemicals Co Ltd is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Polymer Biochemicals Co Ltd (002476)?
The operating margin of Shandong Polymer Biochemicals Co Ltd is 6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Polymer Biochemicals Co Ltd (002476)?
Revenue at Shandong Polymer Biochemicals Co Ltd is growing +78.0% versus a year earlier (3y avg +0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Polymer Biochemicals Co Ltd (002476)?
Earnings per share at Shandong Polymer Biochemicals Co Ltd are growing −9.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shandong Polymer Biochemicals Co Ltd (002476) hold?
Shandong Polymer Biochemicals Co Ltd holds more cash than debt, 398M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shandong Polymer Biochemicals Co Ltd in the live analysis
One click puts Shandong Polymer Biochemicals Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
